CTOs on the Move

Molekule

www.molekule.com

 
Molekule is a San Francisco-based science and clean technology start-up that has completely reinvented the air purifier using a revolutionary new technology.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Molekule raised $10.1M on 07/19/2017
Molekule raised $25M on 11/01/2018
Molekule raised $58M on 02/25/2020

Similar Companies

Saskatchewan Trucking Association

Saskatchewan Trucking Association is a Regina, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southwest Missouri Office on Aging

Southwest Missouri Office on Aging is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ALLIANCE Home Healthcare

ALLIANCE Home Healthcare is a Palos Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northeast Kidney Foundation

Over 26 million Americans suffer from chronic kidney disease (CKD), including 1.5 million New Yorkers.  Formed in 1972 as a philanthropic gift of Edwin and Rhoda Sperber, the Foundation provides services to patients, family members, the general public and clinical and academic professionals throughout the Northeast.  The mission of the Northeast Kidney Foundation is to improve the quality of life of those affected by kidney disease and related conditions through early identification, intervention, prevention and support services; to promote organ donation; and to empower those we serve to be an effective voice for better healthcare at the local, state and federal levels.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.